secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2022-11-04T23:59:59+00:00
Accession:  0001193125-22-277328
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla reports 36% ORR in NSCLC and meets Go criteria in multiple sarcoma subtypes for BA3011
--------------------------------------------------------------------------------

- NSCLC Phase 2 Part 1: ORR 36% (5/14), 42% in non-squamous (5/12); 1 CR and 4 PRs.
- Sarcoma: Go criteria met for UPS, osteosarcoma, liposarcoma, and synovial sarcoma into Part 2.
- UPS (Phase 1&2, n=10): ORR 50% (4/8 evaluable), 3-month PFS rate 50%, median PFS 6.8 months.
- Osteosarcoma (n=6): 3-month PFS rate 66.7%; liposarcoma (n=6): 66.7%; synovial sarcoma (n=5): 54%.
- FDA supportive of proposed registrational Part 2 study in UPS (n=80, primary endpoint ORR); enrollment expected by year-end 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000119312522277328/0001193125-22-277328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000119312522277328/d416713d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-277328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer